Trial Success - DASL HiCaP & frontMIND

The UCD Cancer Cluster received some positive news recently, with the announcement that our sites were the highest recruiting sites in Ireland for the DASL HiCaP and frontMIND trials. 

DASL HiCaP open at the Mater's Clinical Trial Research Unit, aimed to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.

FrontMIND (also called MOR208C310), on the other hand, was opened at the new haematology trial group at St Vincent's Hospital. This trial compared the effectiveness and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in people with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

For both trials, our sites were the highest recruiter in Ireland and for the DASL HiCaP trial, we were also the 2nd highest recruiter in the UK and Ireland. 

Congratulations to the clinical trial nurses, coordinators, and data managers for all their hard work on these studies! 

More information on FrontMIND can be found (opens in a new window)here. 

More information on DASL HiCaP can be found (opens in a new window)here.